PPA
AKRO

Parametric Portfolio Associates’s Akero Therapeutics AKRO Stock Holding History

Parametric Portfolio Associates’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9,254
Closed -$207K – 3630
2021
Q3 		$207K Sell
9,254
-790
-8% -$17.9K ﹤0.01% 3427
2021
Q2 		$249K Buy
10,044
+1,272
+15% +$35.7K ﹤0.01% 3329
2021
Q1 		$254K Buy
+8,772
New +$266K ﹤0.01% 3783
2020
Q4 		– Sell
-30,045
Closed -$925K – 3990
2020
Q3 		$925K Buy
+30,045
New +$1.05M ﹤0.01% 2970

Other funds holding AKRO

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Parametric Portfolio Associates's AKRO Position: Q4 2021 in Review

Parametric Portfolio Associates sold out of Akero Therapeutics (AKRO) in Q4 2021, closing a stake of 9,254 shares — an estimated $207K sold.

Parametric Portfolio Associates first reported a position in AKRO in Q3 2020 and held it in 4 quarters. The position peaked at $925K in Q3 2020. 97 funds tracked by Wall St. Rank hold AKRO as of Q4 2021.

  • Parametric Portfolio Associates reported no remaining Akero Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 9,254 Akero Therapeutics shares in Q4 2021, an estimated $207K.
  • Parametric Portfolio Associates first reported a position in Akero Therapeutics in Q3 2020 and held it in 4 quarters.
  • Parametric Portfolio Associates's Akero Therapeutics position peaked at $925K in Q3 2020.
  • 97 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2021.

Based on Parametric Portfolio Associates's 13F filing for Q4 2021, filed 15 Feb 2022.